Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.

ABSTRACT: Despite significant advancements in the treatment and outcome of hematologic malignancies, prognosis remains poor for patients who have relapsed or refractory disease. Adoptive T-cell immunotherapy offers novel therapeutics that attempt to utilize the noted graft versus leukemia effect. While CD19 chimeric antigen receptor (CAR)-modified T cells have thus far been the most clinically successful application of adoptive T immunotherapy, further work with antigen specific T cells and CARs that recognize other targets have helped diversify the field to treat a broad spectrum of hematologic malignancies. This article will focus primarily on therapies currently in the clinical trial phase as well as current downfalls or limitations.

SUBMITTER: McLaughlin L 

PROVIDER: S-EPMC4649603 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature